Document is current
Any future updates will be listed below
-
Authors
Murad, John P. https://orcid.org/0000-0003-0637-2414
Christian, Lea
Rosa, Reginaldo https://orcid.org/0000-0003-0984-8959
Ren, Yuwei
Buckley, Alyssa J.
Lee, Eric Hee Jun
Lopez, Lupita S.
Park, Anthony K.
Yang, Jason https://orcid.org/0000-0002-7156-5872
Yamaguchi, Yukiko
Trac, Candi
Adkins, Lauren N.
Chang, Wen-Chung https://orcid.org/0000-0002-1982-0725
Martinez, Catalina
June, Carl H. https://orcid.org/0000-0003-0241-3557
Forman, Stephen J.
Ishihara, Jun https://orcid.org/0000-0002-9083-9859
Lee, John K. https://orcid.org/0000-0002-6570-2180
Stern, Lawrence A.
Priceman, Saul J. https://orcid.org/0000-0002-8136-2112
-
Funding
Funding for this research was provided by:
Prostate Cancer Foundation (PCF TACTICAL AWARD)
- License Information
-
More Information
Article History
Received: 27 September 2024
Accepted: 13 August 2025
First Online: 1 October 2025
Competing interests
: S.J.P. is a scientific advisor and/or receives royalties from Imugene Ltd, Adicet Bio, Port Therapeutics, and Celularity. S.J.P., J.P.M., E.H.J.L. and S.J.F. are listed as co-inventors on a patent on the development of TAG72-targeted CAR-modified T cells for the treatment of TAG72-positive tumours, and S.J.P. and S.J.F. are listed as co-inventors on a patent on the development of PSCA-targeted CAR-modified T cells for the treatment of PSCA-positive tumours, owned by COH. S.J.P. and J.P.M. are listed as co-inventors on a patent on the development of PD-L1-targeted IL-12 fusion proteins, co-owned by USC and COH. The other authors declare no competing interests.
